Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome.


Journal

Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241

Informations de publication

Date de publication:
15 Apr 2020
Historique:
pubmed: 26 12 2019
medline: 2 10 2020
entrez: 26 12 2019
Statut: ppublish

Résumé

Secondary pulmonary alveolar proteinosis (sPAP) is a complication of myelodysplastic syndrome (MDS). A 60-year-old woman was diagnosed with MDS with excess blasts-1. Fifty-four months after the initial diagnosis, treatment with azacitidine was initiated. Seventy-three months after the diagnosis, a bone marrow examination revealed increased myeloblasts, at which time computed tomography showed diffuse ground-glass opacities and interlobular septal thickening in the bilateral lower lung fields. A lung biopsy revealed the presence of PAP; therefore, the clinical diagnosis of MDS/sPAP was confirmed. Careful attention should be paid to the development of sPAP in MDS patients with pulmonary lesions during azacitidine treatment.

Identifiants

pubmed: 31875636
doi: 10.2169/internalmedicine.3770-19
pmc: PMC7205539
doi:

Substances chimiques

Azacitidine M801H13NRU

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1081-1086

Commentaires et corrections

Type : CommentIn

Références

Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
J Clin Oncol. 2002 May 15;20(10):2429-40
pubmed: 12011120
Leukemia. 2017 Aug;31(8):1661-1670
pubmed: 28484264
Ann Hematol. 2019 Jun;98(6):1367-1381
pubmed: 30854574
Int J Hematol. 2009 Oct;90(3):407-412
pubmed: 19693450
Bone Marrow Transplant. 2006 Oct;38(8):581-2
pubmed: 16953205
Leuk Res. 2002 Jun;26(6):591-5
pubmed: 12007507
BMC Pulm Med. 2014 Mar 05;14:37
pubmed: 24597668
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Blood. 2012 Sep 20;120(12):2454-65
pubmed: 22740453
J Clin Oncol. 2007 Aug 10;25(23):3503-10
pubmed: 17687155
Oncotarget. 2017 Apr 25;8(17):28812-28825
pubmed: 28427179
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):788-94
pubmed: 8118651
Radiology. 1999 Apr;211(1):155-60
pubmed: 10189465
Stem Cells Transl Med. 2014 Oct;3(10):1188-98
pubmed: 25122688
Intern Med. 2003 Feb;42(2):187-90
pubmed: 12636240
Blood. 1997 Mar 15;89(6):2079-88
pubmed: 9058730
Nat Commun. 2017 Apr 21;8:15099
pubmed: 28429724
Blood. 2014 Feb 6;123(6):809-21
pubmed: 24227816
N Engl J Med. 1958 Jun 5;258(23):1123-42
pubmed: 13552931
Blood Adv. 2019 Aug 13;3(15):2424-2435
pubmed: 31409584
Int J Hematol. 2020 Feb;111(2):311-316
pubmed: 31515708
Medicine (Baltimore). 2017 Nov;96(44):e8481
pubmed: 29095306
Blood. 2003 Oct 15;102(8):2777-85
pubmed: 12855568
Exp Hematol. 2014 Jun;42(6):477-86.e4
pubmed: 24607955
Haematologica. 2011 Mar;96(3):441-9
pubmed: 21134982
J Exp Med. 1999 Sep 20;190(6):875-80
pubmed: 10499925
Eur Respir J. 2011 Feb;37(2):465-8
pubmed: 21282812
BMC Pulm Med. 2015 Aug 12;15:87
pubmed: 26264606
Blood. 2016 Jan 21;127(3):333-42
pubmed: 26450985

Auteurs

Miki Hashimoto (M)

Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Hidehiro Itonaga (H)

Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan.

Yasuhito Nannya (Y)

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Japan.

Hirokazu Taniguchi (H)

Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Yuichi Fukuda (Y)

Department of Respiratory Medicine, Sasebo City General Hospital, Japan.

Takafumi Furumoto (T)

Department of Hematology, Sasebo City General Hospital, Japan.

Machiko Fujioka (M)

Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Department of Hematology, Nagasaki University Hospital, Japan.

Sachie Kasai (S)

Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Japan.

Masataka Taguchi (M)

Department of Hematology, Nagasaki University Hospital, Japan.

Hiroaki Taniguchi (H)

Department of Hematology, Sasebo City General Hospital, Japan.

Shinya Sato (S)

Department of Hematology, Nagasaki University Hospital, Japan.

Yasushi Sawayama (Y)

Department of Hematology, Nagasaki University Hospital, Japan.

Sunao Atogami (S)

Department of Clinical Laboratory, Sasebo City General Hospital, Japan.

Keisuke Iwasaki (K)

Department of Pathology, Sasebo City General Hospital, Japan.

Tomoko Hata (T)

Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan.

Hiroshi Soda (H)

Department of Respiratory Medicine, Sasebo City General Hospital, Japan.

Yukiyoshi Moriuchi (Y)

Department of Hematology, Sasebo City General Hospital, Japan.

Koh Nakata (K)

Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Japan.

Seishi Ogawa (S)

Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Japan.

Yasushi Miyazaki (Y)

Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Department of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan.
Department of Hematology, Nagasaki University Hospital, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH